Sangamo Therapeutics (SGMO) Stock Price Up 0%

Sangamo Therapeutics Inc (NASDAQ:SGMO)’s share price shot up 0% on Friday . The stock traded as high as $18.45 and last traded at $18.30. 2,270,479 shares traded hands during mid-day trading, an increase of 51% from the average session volume of 1,507,231 shares. The stock had previously closed at $18.30.

Several brokerages have recently weighed in on SGMO. Zacks Investment Research cut Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, January 5th. Piper Jaffray Companies set a $25.00 price target on Sangamo Therapeutics and gave the company a “buy” rating in a research report on Wednesday, January 3rd. BidaskClub upgraded Sangamo Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, December 29th. Barclays began coverage on Sangamo Therapeutics in a research report on Wednesday, November 22nd. They issued an “overweight” rating and a $20.00 price target for the company. Finally, Jefferies Group reiterated a “buy” rating and issued a $18.00 price target on shares of Sangamo Therapeutics in a research report on Friday, October 13th. Four analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $18.83.

The stock has a market cap of $1,550.00, a PE ratio of -26.52 and a beta of 3.15. The company has a current ratio of 5.64, a quick ratio of 5.64 and a debt-to-equity ratio of 0.02.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.15) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.19) by $0.04. Sangamo Therapeutics had a negative return on equity of 31.81% and a negative net margin of 157.66%. The business had revenue of $11.81 million during the quarter, compared to analysts’ expectations of $10.37 million. During the same period in the previous year, the business earned ($0.27) earnings per share. The firm’s revenue was up 333.0% on a year-over-year basis. equities analysts anticipate that Sangamo Therapeutics Inc will post -0.73 earnings per share for the current fiscal year.

In related news, Director Saira Ramasastry sold 5,000 shares of the business’s stock in a transaction dated Friday, November 17th. The stock was sold at an average price of $14.67, for a total transaction of $73,350.00. Following the completion of the transaction, the director now directly owns 5,000 shares in the company, valued at $73,350. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, VP Curt A. Herberts III sold 11,803 shares of the business’s stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $18.00, for a total value of $212,454.00. Following the transaction, the vice president now owns 27,636 shares of the company’s stock, valued at $497,448. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 58,433 shares of company stock valued at $979,696. 5.50% of the stock is owned by company insiders.

Institutional investors have recently bought and sold shares of the stock. Cookson Peirce & Co. Inc. purchased a new position in shares of Sangamo Therapeutics in the 2nd quarter worth about $317,000. State Street Corp boosted its holdings in shares of Sangamo Therapeutics by 51.6% in the 2nd quarter. State Street Corp now owns 1,868,285 shares of the biopharmaceutical company’s stock worth $16,441,000 after purchasing an additional 636,296 shares in the last quarter. Swiss National Bank boosted its holdings in shares of Sangamo Therapeutics by 26.4% in the 2nd quarter. Swiss National Bank now owns 143,560 shares of the biopharmaceutical company’s stock worth $1,263,000 after purchasing an additional 30,000 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Sangamo Therapeutics by 53.5% in the 2nd quarter. Goldman Sachs Group Inc. now owns 100,176 shares of the biopharmaceutical company’s stock worth $881,000 after purchasing an additional 34,913 shares in the last quarter. Finally, Wells Fargo & Company MN boosted its holdings in shares of Sangamo Therapeutics by 45.8% in the 2nd quarter. Wells Fargo & Company MN now owns 431,234 shares of the biopharmaceutical company’s stock worth $3,795,000 after purchasing an additional 135,464 shares in the last quarter. Institutional investors and hedge funds own 64.33% of the company’s stock.

TRADEMARK VIOLATION WARNING: This news story was originally posted by Community Financial News and is the property of of Community Financial News. If you are viewing this news story on another website, it was copied illegally and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.com-unik.info/2018/01/12/sangamo-therapeutics-sgmo-stock-price-up-0.html.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit